CD8A and neoplasm: In the setting of treatment-naïve metastatic disease, the expeditious initiation of systemic therapy with PULSAR can provide local and systemic control concurrently and, possibly, improve the response to immunotherapy by enriching antigen expression and thus the activation of tumor-specific CD8+ T cells.